R. Lambert-Falls

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Harold J. Burstein, Lyndsay N. Harris, P. Kelly Marcom et al. · Journal of Clinical Oncology · 2003 · 345 citations

Medicine, Oncology, Pharmacology +17

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Harold J. Burstein, Aparna Keshaviah, Ari David Baron et al. · Cancer · 2007 · 212 citations

Medicine, Oncology, Pharmacology +14

Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole

Adam Brufsky, Nigel Bundred, Robert E. Coleman et al. · The Oncologist · 2008 · 175 citations

Medicine, Oncology, Pharmacology +17

P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

Adam Brufsky, Nigel Bundred, RE Coleman et al. · The Breast · 2007 · 15 citations

Medicine, Oncology, Pharmacology +17

Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study

HJ Burstein, Aparna Keshaviah, Aurore Baron et al. · Journal of Clinical Oncology · 2006 · 12 citations

Medicine, Oncology, Pharmacology +17